What is Ips Research?
Established in 1996 by Dr. Louise Thurman, Ips Research operates as a premier entity in the clinical trial sector, prioritizing data integrity and patient-centric methodologies. By bridging the gap between pharmaceutical innovation and clinical practice, the organization has emerged as a critical partner for global life sciences firms. Its commitment to high-fidelity data collection and rigorous research standards has positioned it as a leader in the United States, facilitating advancements in medical science through a robust network of clinical sites and professional expertise.
How much funding has Ips Research raised?
Ips Research has raised a total of $400K across 2 funding rounds:
Debt
$150K
Debt
$250K
Debt (2020): $150K with participation from PPP
Debt (2021): $250K led by PPP
Key Investors in Ips Research
PPP
Public-Private Partnership
What's next for Ips Research?
With the recent influx of capital, Ips Research is well-positioned to scale its clinical trial operations and enhance its technological capabilities in data management. The company is expected to leverage this financing to broaden its therapeutic reach and deepen its partnerships with pharmaceutical developers. As the clinical research landscape becomes increasingly complex, Ips Research's focus on operational efficiency and high-quality data output will likely serve as a primary driver for its continued expansion and long-term competitive advantage in the global healthcare market.
See full Ips Research company page
